LIDDS Appoints Matthew Lindon as Chief Scientific Officer, Effective March 1, 2022
December 20, 2021 at 02:00 pm
LIDDS AB (publ) announced that Matthew Lindon has been appointed Chief Scientific Officer (CSO) of LIDDS AB. Matthew Lindon has over 20 years experience of drug discovery and development from the pharmaceutical sector and will assume his new role on March 1, 2022. Matthew has a strong background from the pharmaceutical sector where he has been working as Senior Director and Global Project Leader with a focus on drug discovery and early clinical development at GSK, and most recently at AstraZeneca.